AI Joins the Fight: New Tool Aims to Revolutionize ALS Trial Access

SEATTLE, WA – April 29, 2026 – The nonprofit EverythingALS has launched an artificial intelligence platform designed to tackle one of the most significant hurdles in the fight against amyotrophic lateral sclerosis (ALS): connecting patients with clinical trials. The new tool, named SAVA AI, aims to democratize access to potentially life-altering research, moving beyond the traditional barriers of geography and chance.

Available for free on the EverythingALS website and app, SAVA AI uses a patient's self-reported health data to find and suggest clinical trials for which they may be eligible. This initiative directly addresses a long-standing frustration within the ALS community, where finding and enrolling in trials is often a confusing and arduous process.

“We created SAVA AI because access to clinical trials should never depend on chance, geography, or connections,” said Indu Navar, Founder of EverythingALS, in a statement. “By harnessing AI and citizen-driven research, we’re giving patients the power to find opportunities that could change the course of their own disease journey, and accelerating the entire community’s path toward a cure."

Overcoming a Critical Hurdle in ALS Research

The search for effective ALS treatments has been hampered by notoriously difficult clinical trial recruitment. Historically, a mere 5-10% of people living with ALS (pALS) participate in clinical trials. This bottleneck is not due to a lack of will, but a confluence of systemic obstacles.

Many patients are simply unaware of trials that could be a match for them, or their local physicians may not have information on every available study, particularly those outside their immediate network. Furthermore, trial eligibility criteria are often incredibly specific, narrowing the pool of potential participants based on disease duration, functional capacity, or the presence of rare genetic mutations. This can lead to a desperate and often fruitless search for patients and their families.

Geographical disparity adds another layer of inequity. Major research centers are often concentrated in urban areas, leaving patients in rural or underserved regions with limited options. SAVA AI was designed to level this playing field, providing a centralized, intelligent resource accessible from anywhere with an internet connection.

How SAVA AI Aims to Change the Game

SAVA AI operates on a model of “citizen-driven research.” Patients are invited to securely provide their health information on the platform. The system's AI then gets to work. According to EverythingALS, the platform is powered by multiple collaborating AI agents—one that tracks patient health data and another that constantly scours the clinical trial landscape to identify and match patients with the most relevant studies.

When a potential match is found, the patient receives a real-time alert, which they can then discuss with their physician and family. This shift from a passive waiting game to an active, informed process gives patients a renewed sense of agency over their healthcare journey.

The platform's focus on ALS is a key differentiator in a growing field of health-tech tools. While other AI-powered trial finders exist, such as the NIH's TrialGPT and platforms from companies like TrialX, SAVA AI is built from the ground up for the specific complexities of this neurodegenerative disease. Its namesake, a friend of the organization living with ALS in Amsterdam, underscores the deeply personal mission driving the technology: to move from “Care to Cure.”

The Promise and Peril of AI in Healthcare

As AI becomes more integrated into medicine, it brings both immense promise and significant ethical questions, particularly concerning data privacy. EverythingALS states that SAVA AI uses “only EverythingALS synthesized data and insights, ensuring security, privacy and accuracy.”

This use of synthesized data—a method of creating artificial datasets that mimic the statistical properties of real patient data without revealing individual identities—is a critical step toward protecting patient privacy. It allows researchers to glean valuable insights while minimizing the risk of re-identification, a major concern under regulations like HIPAA in the United States and GDPR in Europe.

However, the broader use of AI in healthcare is not without challenges. Experts caution about the potential for algorithmic bias, where AI systems trained on non-diverse datasets can perpetuate or even amplify existing health inequities. Ironically, a tool like SAVA AI could help mitigate this very problem. By breaking down geographical and informational barriers, it has the potential to bring a more diverse pool of patients into clinical trials, which is essential for developing treatments that are effective for everyone.

Still, the importance of human oversight remains paramount. Medical and AI ethicists consistently stress that AI should serve as a powerful tool to augment, not replace, the judgment of clinicians and the informed decisions of patients.

A Collaborative Ecosystem for a Cure

SAVA AI is not merely a standalone app but the public-facing component of a much larger strategy. EverythingALS, which operates under the 501(c)(3) Peter Cohen Foundation, has cultivated a unique ecosystem dedicated to accelerating ALS research through an “open innovation model.”

The organization has built a network that includes thousands of subscribers and research participants, and it actively collaborates with top-tier academic institutions like Harvard, MIT, and Temple University, as well as a consortium of 22 pharmaceutical companies. The collective, anonymized data gathered through its platform, including SAVA AI, is made available to this network of researchers, creating a shared resource intended to strengthen the entire ALS research community.

This collaborative, non-profit model is sustained through grants and donations, allowing the SAVA AI tool to remain free for users. By merging with other organizations like CureALS and launching ambitious long-term plans like its “Vision 2030 Initiative,” EverythingALS is positioning itself as a central hub for technology-driven progress in the field. The launch of SAVA AI is a pivotal step in that journey, transforming the abstract promise of data science into a tangible tool of hope for patients and families affected by ALS.